Teladoc Health, Inc. (NYSE:TDOC) Receives $7.80 Consensus Target Price from Analysts

Teladoc Health, Inc. (NYSE:TDOC) has received a consensus recommendation of “Hold” from the nineteen brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and five have given a buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $7.5625.

A number of analysts recently issued reports on the company. TD Cowen lowered their price target on Teladoc Health from $8.00 to $6.00 and set a “hold” rating for the company in a report on Thursday, February 26th. Bank of America raised Teladoc Health from a “neutral” rating to a “buy” rating and set a $7.00 target price for the company in a research report on Thursday, February 26th. Stifel Nicolaus lowered their target price on Teladoc Health from $8.00 to $6.00 and set a “hold” rating for the company in a report on Thursday, February 26th. Wells Fargo & Company dropped their price target on Teladoc Health from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Thursday, February 26th. Finally, Zacks Research downgraded Teladoc Health from a “strong-buy” rating to a “hold” rating in a report on Monday, November 10th.

Insider Transactions at Teladoc Health

In other Teladoc Health news, CEO Charles Divita III sold 17,138 shares of the firm’s stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $7.63, for a total transaction of $130,762.94. Following the transaction, the chief executive officer owned 201,036 shares of the company’s stock, valued at approximately $1,533,904.68. This trade represents a 7.86% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.58% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Teladoc Health

Hedge funds and other institutional investors have recently modified their holdings of the business. Jupiter Asset Management Ltd. boosted its position in Teladoc Health by 293.9% during the 4th quarter. Jupiter Asset Management Ltd. now owns 3,860,076 shares of the health services provider’s stock valued at $27,021,000 after acquiring an additional 2,880,008 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Teladoc Health by 23.8% during the third quarter. Dimensional Fund Advisors LP now owns 6,889,194 shares of the health services provider’s stock valued at $53,260,000 after purchasing an additional 1,325,106 shares in the last quarter. Trexquant Investment LP purchased a new position in Teladoc Health in the fourth quarter valued at about $9,156,000. Monaco Asset Management SAM grew its stake in Teladoc Health by 159.2% in the fourth quarter. Monaco Asset Management SAM now owns 1,956,947 shares of the health services provider’s stock valued at $13,699,000 after purchasing an additional 1,201,947 shares during the last quarter. Finally, Allianz Asset Management GmbH raised its holdings in Teladoc Health by 189.2% in the third quarter. Allianz Asset Management GmbH now owns 1,619,391 shares of the health services provider’s stock worth $12,518,000 after purchasing an additional 1,059,458 shares in the last quarter. 76.82% of the stock is currently owned by institutional investors.

Teladoc Health Trading Up 4.4%

NYSE TDOC opened at $5.31 on Tuesday. The company’s 50-day moving average price is $5.75 and its 200-day moving average price is $7.11. The company has a current ratio of 2.77, a quick ratio of 2.67 and a debt-to-equity ratio of 0.72. The stock has a market cap of $946.41 million, a PE ratio of -4.65 and a beta of 2.13. Teladoc Health has a 12 month low of $4.40 and a 12 month high of $9.77.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings data on Wednesday, February 25th. The health services provider reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.05. The company had revenue of $642.27 million during the quarter, compared to analyst estimates of $635.33 million. Teladoc Health had a negative net margin of 7.92% and a negative return on equity of 9.13%. The firm’s revenue for the quarter was up .3% on a year-over-year basis. During the same quarter last year, the business posted ($0.28) EPS. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. Equities research analysts forecast that Teladoc Health will post -1.16 earnings per share for the current year.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.